Phellodendron amurense for Health & Longevity - Quick Reference Sheet

Phellodendron amurense for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Phellodendron amurense (Amur cork tree) inner bark is a dietary supplement used for blood sugar, cholesterol, stress, weight, and joint comfort. No controlled trial has tested oral bark alone; positive human studies use manufacturer-funded herbal blends with inconsistent results. Because oral bark blocks liver enzymes and cellular pumps that clear medications and risks heart-rhythm, potassium, kidney, and liver strain, standalone use remains unproven for longevity. (Full Review)

Protocol

Standalone bark extract (Nexrutine regimen)
1,500 mg/day orally
Administered orally at 500 mg three times daily with meals for 1 to 2 months
Magnolia & Phellodendron blend (Relora)
500–750 mg/day orally
Dosed at 250 mg twice daily for 4 weeks or 250 mg three times daily for 6 weeks
Phellodendron & Citrus sinensis blend (NP 06-1 joint/metabolic regimen)
1,480 mg/day orally
Administered orally as two 370 mg capsules twice daily for 8 weeks
Time to effect
Joint pain and lipid changes
8 weeks
LDL-C, fasting glucose, overweight CRP, and knee osteoarthritis pain and mobility changes in NP 06-1 trials
Cortisol and mood shifts
4–6 weeks
Salivary cortisol and perceived stress reduction at 4 weeks; state anxiety reduction at 6 weeks on Relora
Postprandial glucose attenuation
15–75 minutes
Acute post-dextrose serum glucose attenuation following a single blend dose

Benefits

Contraindications
  • Pregnant or lactating women, neonates, and G6PD-deficient individuals
  • Individuals with baseline QTc prolongation or hypokalemia
  • Organ transplant recipients and patients on narrow-therapeutic-index CYP2D6, CYP2C9, or CYP3A4 drugs without drug-level monitoring
  • Competitive athletes subject to WADA anti-doping testing
  • Individuals with moderate-to-severe renal or hepatic impairment
Key Interactions
  • Calcineurin inhibitor immunosuppressants (cyclosporine A, tacrolimus)
  • Prescription CYP2D6 substrates (metoprolol, carvedilol, fluoxetine, paroxetine, venlafaxine, tamoxifen, codeine)
  • Prescription CYP2C9 substrates (warfarin, losartan, irbesartan, glipizide, celecoxib)
  • Prescription CYP3A4 substrates (simvastatin, atorvastatin, amlodipine, diltiazem, midazolam, apixaban)
  • Antidiabetic and antihypertensive drugs (metformin, insulin, glimepiride, lisinopril, valsartan) (theoretical)
  • QT-prolonging medications (azithromycin, ciprofloxacin, amiodarone, sotalol, ondansetron, haloperidol) (theoretical)
  • Over-the-counter medications (dextromethorphan, ibuprofen, naproxen, diphenhydramine, omeprazole)
  • Berberine-containing and metabolic/sedative supplements (berberine, goldenseal, Oregon grape, Coptis chinensis, ashwagandha, valerian, alpha-lipoic acid) (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Cytochrome P450 & P-glycoprotein drug interaction toxicity; gastrointestinal distress; QTc interval prolongation & electrolyte shifts; neonatal hyperbilirubinemia & kernicterus risk
  • Speculative: High-dose renal tubular degeneration & limonin hepatotoxicity; unintentional anti-doping violation

Monitoring

Marker Target Why
Fasting plasma glucose 70–99 mg/dL (standard reference range) Efficacy marker: expected to decrease in overweight or insulin-resistant users (10–12 hour overnight fast; paired with HbA1c at 12 weeks).
LDL-C & fasting triglycerides LDL-C < 100 mg/dL; triglycerides < 150 mg/dL (standard reference range) Efficacy marker: both decreased over 8 weeks in NP 06-1 trials (10–12 hour fast at baseline and week 8).
High-sensitivity CRP < 3.0 mg/L (standard reference range) Efficacy marker: decreased by 49% in overweight osteoarthritis patients on NP 06-1.
Diurnal salivary cortisol No established target; percent reduction from individual baseline Efficacy marker: composite morning, noon, and evening salivary cortisol fell 18% on Relora (baseline and week 4).
Serum ALT, AST & total bilirubin ALT 7–56 U/L; AST 8–33 U/L; bilirubin 0.1–1.2 mg/dL (standard reference range) Safety check: detects limonoid hepatotoxicity or berberine bilirubin displacement (discontinued if ALT/AST > 3× upper limit of normal or bilirubin rises).
Serum creatinine & eGFR Creatinine 0.6–1.3 mg/dL; eGFR ≥ 60 mL/min/1.73 m² (standard reference range) Safety check: monitors for high-dose renal tubular stress seen in rat studies (baseline, week 4, and week 8).
Serum potassium & 12-lead electrocardiogram (QTc) Potassium 3.5–5.0 mmol/L; QTc ≤ 450 ms in men, ≤ 470 ms in women (standard reference range) Safety check: high-dose Nexrutine caused Grade 1 QTc prolongation (14.3%) and Grade 3 hypokalemia (4.8%) (baseline and week 4 at ≥ 1,500 mg/day or with QT-prolonging drugs).

Cadence: Baseline, week 4 (potassium, QTc, and liver/kidney safety markers), weeks 8–12 (lipid, glucose, CRP, or salivary cortisol efficacy response), and every 3–6 months during extended cyclical use.

Qualitative Assessment

  • Perceived stress and mood stability: Changes in daily tension, irritability, fatigue, and stress-induced snacking over 4 to 6 weeks on the Profile of Mood States (POMS) or Perceived Stress Scale (PSS).
  • Joint comfort and walking mobility: Knee pain during stair climbing, morning stiffness, and walking distance over 8 weeks on the Lequesne Algofunctional Index.
  • Sleep continuity and nocturia frequency: Nighttime awakenings and lower urinary tract storage symptoms on the International Prostate Symptom Score (IPSS) and Athens Insomnia Scale.
  • Gastrointestinal tolerance: Daily observation for early warning signs of alkaloid intolerance, including post-meal heartburn, nausea, abdominal cramping, or loose stools.